Home/Filings/4/0001209191-21-023075
4//SEC Filing

SMISEK JEFFERY A 4

Accession 0001209191-21-023075

CIK 0001733257other

Filed

Mar 24, 8:00 PM ET

Accepted

Mar 25, 6:08 PM ET

Size

21.4 KB

Accession

0001209191-21-023075

Insider Transaction Report

Form 4
Period: 2021-03-23
Transactions
  • Conversion

    Common Stock

    2021-03-23+272,2451,606,306 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2021-03-23141,9280 total(indirect: See footnote)
    Common Stock (141,928 underlying)
  • Conversion

    Series D Preferred Stock

    2021-03-23272,2450 total(indirect: See footnote)
    Common Stock (272,245 underlying)
  • Conversion

    Common Stock

    2021-03-23+894,955894,955 total(indirect: See footnote)
  • Conversion

    Common Stock

    2021-03-23+297,1781,334,061 total(indirect: See footnote)
  • Conversion

    Common Stock

    2021-03-23+141,9281,036,883 total(indirect: See footnote)
  • Purchase

    Common Stock

    2021-03-23$17.00/sh+88,235$1,499,9951,694,541 total(indirect: See footnote)
  • Conversion

    Series A Preferred Stock

    2021-03-23894,9550 total(indirect: See footnote)
    Common Stock (894,955 underlying)
  • Conversion

    Series C Preferred Stock

    2021-03-23297,1780 total(indirect: See footnote)
    Common Stock (297,178 underlying)
Footnotes (2)
  • [F1]Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.
  • [F2]The securities are held by Flight Partners Management LLC ("Flight Partners Capital"). The Reporting Person is the president of Flight Partners Capital.

Issuer

Finch Therapeutics Group, Inc.

CIK 0001733257

Entity typeother

Related Parties

1
  • filerCIK 0001193038

Filing Metadata

Form type
4
Filed
Mar 24, 8:00 PM ET
Accepted
Mar 25, 6:08 PM ET
Size
21.4 KB